Clinical Trial Update: Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma [Phase 2]

View source ↗

Summary

Phase II trial evaluating a triplet regimen of oxaliplatin, irinotecan, and capecitabine in advanced gastric and gastroesophageal junction cancers; results were…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Gastroesophageal Junction
• Diffuse Adenocarcinoma of the Stomach
• Gastric Cancer
• Intestinal Adenocarcinoma of the Stomach
• Mixed Adenocarcinoma of the Stomach
• Stage Iiia Gastric Cancer
• Stage Iiib Gastric Cancer
• Stage Iiic Gastric Cancer

Drugs mentioned

• Capecitabine (Xeloda) (Capecitabine)
• Irinotecan (Camptosar) (Irinotecan)
• Oxaliplatin (Eloxatin) (oxaliplatin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach | Phase 2 | Status: COMPLETED | Results posted: 2015-05-01